Tilray Brands believes it can get into the medical marijuana business in the U.S. pretty quickly if the Biden administration reclassifies cannabis as a Schedule 3 drug sometime this year, CEO Irwin Simon tells WSJ.
As one of the largest medical cannabis businesses in both Canada and Europe, Tilray has “the expertise in growth, the research and the know-how” to launch medical cannabis operations in the U.S. expeditiously, whether through a greenfield approach or by acquiring an existing player in the States, Simon says.
Recent Comments